Drug abuse and mental illness
Drug abuse represents one of the most significant health challenges in the 21st century, with major impacts on individual health and societal support. Closely linked to this problem are the both causative and resultant effects on mental health. Faculty in this group are investigating the cellular and behavioral effects of drugs of abuse, employing genetic through behavioral techniques. The goal of these studies is to improve the treatment of medical disorders through a better understanding of the pharmacology of agents and their mechanisms of action with the purpose of developing safer and more effective pharmacological therapies as well as elucidating the basic mechanisms of drug actions and addiction.
Hamid Akbarali, Ph.D.
Mechanism of action of opiates, cannabinoids and nicotine in enteric and sensory neurons
Matthew Banks, PharmD., Ph.D.
Understanding the neurobehavioral mechanisms of drug choice over other competing non-drug reinforcers toward the goal of developing pharmacological and behavioral treatment strategies for drug addiction
Patrick M. Beardsley, Ph.D.
Behavioral pharmacology of drugs of abuse; development of medication for CNS disorders
Jill C. Bettinger, Ph.D.
Physiological effects of alcohol on synaptic transmission and behavior
Darlene H. Brunzell, Ph.D.
Molecular, genetic and behavioral contributions to etiology of drug abuse and mental illness in males and females
M. Imad Damaj, Ph.D.
Pharmacology of nicotine and nicotinic receptors; behavioral pharmacology; mouse genetics, drug development
Andrew G. Davies, Ph.D.
Neurobiology of alcohol intoxication and tolerance; C. elegans behavioral genetics and neuroscience
William L. Dewey, Ph.D.
Action of drugs of abuse, with emphasis on the opioids; mechanisms of opioid tolerance and physical dependence
Michael S. Grotewiel, Ph.D.
Molecular genetic bases of aging and alcohol-related behavior in the fruit fly Drosophila melanogaster; understanding the molecular events underlying aging (especially age-related functional declines) and nervous system responses to acute exposure to alcohol
Kurt F. Hauser, Ph.D.
Human immunodeficiency virus type 1 neuropathogenesis and its relationship to substance abuse; molecular mechanisms by which drug abuse alters CNS organization and function
Kenneth S. Kendler, M.D.
Genetic epidemiology of schizophrenia, depression, alcoholism and anxiety disorders; twin studies; family studies; biometrical models for psychiatric genetics; large scale genome-wide association and sequencing studies of schizophrenia, depression and alcohol dependence
Aron H. Lichtman, Ph.D.
Physiological function of the endocannabinoid system; mechanisms and pharmacological effects of THC and other cannabinoids
Javier Maeso, Ph.D.
We are interested in the structure, function and regulation of G protein-coupled receptors (GPCRs), their interacting proteins, and psychiatric disease associations such as schizophrenia, suicide and alcoholism. In addition, our laboratory aims to understand the molecular, cellular and neural circuit mechanisms by which environmental factors and chronic drug exposure alter behavior
A. Rory McQuiston, Ph.D.
Ventral hippocampal network function in activities such as aggression, anxiety, and consummatory behaviors
Michael F. Miles, M.D., Ph.D.
Molecular mechanisms of experience-dependent plasticity occurring with drug abuse; molecular mechanisms underlying sensitization to cocaine or ethanol
S. Stevens Negus, Ph.D.
Behavioral pharmacology of analgesic and abused drugs
Gretchen N. Neigh, Ph.D.
Neurobiology of depression and anxiety; psychoneuroimmunology; psychoneuroendocrinology; neurobiology of affective disorders co-morbid with somatic disease
Katherine L. Nicholson, Ph.D., D.V.M.
Behavioral pharmacology of drugs of abuse, particularly drugs that alter glutamate neurotransmission
Andrew K. Ottens, Ph.D.
Molecular mechanisms underlying juvenile behavioral deficits following environmental tobacco smoke exposure and its influence on later-life substance dependency
Joseph Porter, Ph.D.
Behavioral pharmacology of antipsychotic drugs used for the treatment of schizophrenia; animal models for schizophrenia, depression and anxiety
Carmen Sato-Bigbee, Ph.D.
Regulation of oligodendrocyte differentiation and myelin formation during brain development; mechanisms of demyelination/remyelination in multiple sclerosis; perinatal opioid exposure and central nervous development
Joel Schlosburg, Ph.D.
Behavioral pharmacology of maladaptive processes leading from drug use to uncontrolled addiction, and potential therapeutic targets that may emerge from understanding the neurobiological changes that underlie this progression.
Dana E. Selley, Ph.D.
Mechanism of action of G-protein-coupled receptors, especially those that mediate the effects of psychoactive drugs such as opiates, cannabinoids and antidepressants
Keith L. Shelton, Ph.D.
Behavioral pharmacology of abused inhalants, stimulants and alcohol; neurochemical mechanisms of subjective drug effects; behavioral mechanisms of relapse
Laura J. Sim-Selley, Ph.D.
Functional neuroanatomy of G-protein-coupled receptors, opioid and cannabinoid receptors; tolerance and dependence
Sandra P. Welch, Ph.D.
Cellular pharmacology, particularly the role of free intracellular calcium in tolerance and physical dependence to drugs of abuse; endocrine modulation of tolerance; second messenger systems
Jennifer Wolstenholme, Ph.D.
Mechanisms underlying the neural regulation of neuroendocrine, emotional and behavioral responses and how they mediate risk for neurodevelopmental diseases, specifically social stress and alcohol use in adolescents